Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: Active surveillance and focal targeted therapy

BJU International

Volumn 108, Issue 7, 2011, Pages 1074-1085

  Mouraviev, Vladimir ^a   Villers, Arnauld ^b   Bostwick, David G ^c   Wheeler, Thomas M ^d   Montironi, Rodolfo ^e   Polascik, Thomas J ^f  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIV LILLE   (France)

^c BOSTWICK LABORATORIES   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

focal therapy; histopathology; pathological stage; prostate cancer; radical prostatectomy

Indexed keywords

ABLATION THERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CRYOTHERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; EARLY CANCER; GLEASON SCORE; HIGH INTENSITY FOCUSED ULTRASOUND; HISTOPATHOLOGY; HUMAN; MULTIPLE CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENT CANCER; REVIEW; SYSTEMATIC REVIEW; TUMOR LOCALIZATION; TUMOR VOLUME;

DISEASE PROGRESSION; HUMANS; MALE; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR BURDEN;

EID: 80052796249     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.10039.x     Document Type: Review

References (81)

1. Ahmed HU, Emberton M,. Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way? World J Urol 2008; 26: 457-67
2. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR,. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 2004; 22: 2141-9 (Pubitemid 41095147)
3. Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT,. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 2006; 98: 1134-41 (Pubitemid 44288788)
4. Ohori M, Scardino PT,. Localized prostate cancer. Curr Probl Surg 2002; 39: 833-957
5. Ramos CG, Carvalhal GF, Smith DS, Mager DE, Catalona WJ,. Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer. J Urol 1999; 161: 1525-9 (Pubitemid 29420811)
6. Caso JR, Tsivian M, Mouraviev V, Polascik TJ, Moul JW,. Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer. BJU Int 2010
7. Ohori M, Kattan M, Scardino PT, Wheeler TM,. Radical prostatectomy for carcinoma of the prostate. Mod Pathol 2004; 17: 349-59 (Pubitemid 41646612)
8. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM,. Biological determinants of cancer progression in men with prostate cancer. JAMA 1999; 281: 1395-400 (Pubitemid 29190217)
9. Desireddi NV, Roehl KA, Loeb S, et al,. Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era. Urology 2007; 70: 950-5 (Pubitemid 350192577)
10. Hernandez DJ, Nielsen ME, Han M, et al,. Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy. Urology 2008; 72: 172-6
11. Bianco FJ Jr, Wood DP Jr, Cher ML, Powell IJ, Souza JW, Pontes JE,. Ten-year survival after radical prostatectomy: specimen Gleason score is the predictor in organ-confined prostate cancer. Clin Prostate Cancer 2003; 1: 242-7 (Pubitemid 37021461)
12. Chun FK, Graefen M, Zacharias M, et al. Anatomic radical retropubic prostatectomy-long-term recurrence-free survival rates for localized prostate cancer. World J Urol 2006; 24: 273-80 (Pubitemid 44138182)
13. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H,. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000; 164: 101-5 (Pubitemid 30434268)
14. Polascik TJ, Mayes JM, Sun L, Madden JF, Moul JW, Mouraviev V,. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Prostate 2008; 68: 1380-6
15. Onik G, Mikus P, Rubinsky B,. Irreversible electroporation: implications for prostate ablation. Technol Cancer Res Treat 2007; 6: 295-300 (Pubitemid 47340121)
16. Sobin LH, Wittekind C, eds. International Union Against Cancer (UICC): TNM Classification of Malignant Tumors, 6th edn. New York: Wiley-Liss, 2002: 184-7
17. Eichelberger LE, Cheng L,. Does pT2b prostate carcinoma exist? Critical appraisal of the 2002 TNM classification of prostate carcinoma. Cancer 2004; 100: 2573-6 (Pubitemid 38715761)
18. Hong SK, Han BK, Chung JS, et al,. Evaluation of pT2 subdivisions in the TNM staging system for prostate cancer. BJU Int 2008; 102: 1092-6
19. DeCastro GJ, McCann T, Benson MC, McKiernan JM,. Pathologic T2 stage subgroups and recurrence-free survival after radical prostatectomy. Urology 2008; 72: 1214-8
20. Bastacky SI, Wojno KJ, Walsh PC, Carmichael MJ, Epstein JI,. Pathological features of hereditary prostate cancer. J Urol 1995; 153: 987-92
21. Smith RP, Beriwal S, Komanduri K, Gibbons E, Benoit R,. Planning based on postneedle volume with early dosimetric assessment is beneficial for Cesium-131 permanent prostate seed implantation. Brachytherapy 2008; 7: 237-41
22. Cheng L, Jones TD, Pan CX, Barbarin A, Eble JN, Koch MO,. Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens. Mod Pathol 2005; 18: 1022-6 (Pubitemid 41224491)
23. Cheng L, Poulos CK, Pan CX, et al,. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens. J Urol 2005; 174: 898-902 (Pubitemid 41140625)
24. Haffner J, Potiron E, Bouye S, et al,. Peripheral zone prostate cancers: location and intraprostatic patterns of spread at histopathology. Prostate 2009; 69: 276-82
25. Muezzinoglu A, Frolov M, Ohori M, Scardino P, Ayala G, Wheeler T,. Clinicopathological significance of multifocal prostate cancer. Abstracts of Annual meeting of USCAP, 2006 Modern Pathol, (#695). 2006; 19 (Suppl. 1s): 151A
26. Wise AM, Stamey TA, McNeal JE, Clayton JL,. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. Urology 2002; 60: 264-9 (Pubitemid 34831770)
27. Yoon GS, Wang W, Osunkoya AO, Lane Z, Partin AW, Epstein JI,. Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma. J Urol 2008; 179: 2203-6; discussion 2206
28. Ward JF, Nakanishi H, Pisters L, Babaian RJ, Troncoso P,. Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy. BJU Int 2009; 104: 490-7
29. Meiers I, Waters DJ, Bostwick DG,. Preoperative prediction of multifocal prostate cancer and application of focal therapy: review 2007. Urology 2007; 70: 3-8
30. Narayanan R, Werahera PN, Barqawi A, et al,. Adaptation of a 3D prostate cancer atlas for transrectal ultrasound guided target-specific biopsy. Phys Med Biol 2008; 53: N397-406
31. Noguchi M, Stamey TA, McNeal JE, Nolley R,. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol 2003; 170: 459-63 (Pubitemid 36870224)
32. Arora R, Koch MO, Eble JN, Ulbright TM, Li L, Cheng L,. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 2004; 100: 2362-6 (Pubitemid 38657883)
33. Rukstalis DB, Goldknopf JL, Crowley EM, Garcia FU,. Prostate cryoablation: a scientific rationale for future modifications. Urology 2002; 60: 19-25 (Pubitemid 36153110)
34. Shibata A, Stamey TA, McNeal JE, Cheng I, Peehl DM,. Genetic polymorphisms in the androgen receptor and type II 5 alpha-reductase genes in prostate enlargement. J Urol 2001; 166: 1560-4 (Pubitemid 32862238)
35. Djavan B, Susani M, Bursa B, Basharkhah A, Simak R, Marberger M,. Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Tech Urol 1999; 5: 139-42 (Pubitemid 29501407)
36. Horninger W, Berger AP, Rogatsch H, et al,. Characteristics of prostate cancers detected at low PSA levels. Prostate 2004; 58: 232-7 (Pubitemid 38168919)
37. Miller GJ, Cygan JM,. Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. J Urol 1994; 152: 1709-13 (Pubitemid 24322612)
38. Song SY, Kim SR, Ahn G, Choi HY,. Pathologic characteristics of prostatic adenocarcinomas: a mapping analysis of Korean patients. Prostate Cancer Prostatic Dis 2003; 6: 143-7 (Pubitemid 36798382)
39. Ohori M, Eastham JA, Koh H, et al,. Is focal therapy reasonable in patients with early stage prostate cancer (CAP)- an analysis of radical prostatectomy (RP) specimens. J Urol 2006; 175 (Suppl.): 507 (Abstract#1574)
40. Iczkowski KA, Hossain D, Torkko KC, et al,. Preoperative prediction of unifocal, unilateral, margin-negative, and small volume prostate cancer. Urology 2008; 71: 1166-71
41. Karavitakis M, Beckley I, Livni N, Abel P, Winkler M, Ahmed H,. Is focal therapy of localized prostate cancer feasible in the United Kingdom? A histopathological analysis of tumour characteristics and the index lesion. J Endourol 2011; 25: in press
42. Mouraviev V, Mayes JM, Sun L, Madden JF, Moul JW, Polascik TJ,. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 2007; 110: 906-10 (Pubitemid 47257670)
43. Tareen B, Godoy G, Sankin A, Temkin S, Lepor H, Taneja SS,. Laterality alone should not drive selection of candidates for hemi-ablative focal therapy. J Urol 2009; 181: 1082-9; discussion 1089-90
44. Branca RT, Chen YM, Mouraviev V, et al,. iDQC anisotropy map imaging for tumor tissue characterization in vivo. Magn Reson Med 2009; 61: 937-43
45. Saika T, Satoh T, Kusaka N, et al,. Route of administration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model. Cancer Gene Ther 2004; 11: 317-24 (Pubitemid 38586087)
46. Bostwick DG, Shan A, Qian J, et al,. Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma. Cancer 1998; 83: 1995-2002 (Pubitemid 28503732)
47. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH,. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003; 21: 2163-72 (Pubitemid 46606365)
48. Polascik TJ, Mayes JM, Schroeck FR, et al,. Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy. Cancer 2009; 115: 2104-10
49. Epstein JI, Walsh PC, Carmichael M, Brendler CB,. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-74 (Pubitemid 24037911)
50. Schulte RT, Wood DP, Daignault S, Shah RB, Wei JT,. Utility of extended pattern prostate biopsies for tumor localization: pathologic correlations after radical prostatectomy. Cancer 2008; 113: 1559-65
51. Sebo TJ, Cheville JC, Riehle DL, et al,. Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen: a report of 454 cases. Cancer 2001; 91: 2196-204 (Pubitemid 32476386)
52. Anast JW, Andriole GL, Bismar TA, Yan Y, Humphrey PA,. Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population? Urology 2004; 64: 544-50 (Pubitemid 39200755)
53. Renshaw AA, Richie JP, Loughlin KR, Jiroutek M, Chung A, D'Amico AV,. Maximum diameter of prostatic carcinoma is a simple, inexpensive, and independent predictor of prostate-specific antigen failure in radical prostatectomy specimens. Validation in a cohort of 434 patients. Am J Clin Pathol 1999; 111: 641-4 (Pubitemid 29200951)
54. Eichelberger LE, Koch MO, Daggy JK, Ulbright TM, Eble JN, Cheng L,. Predicting tumor volume in radical prostatectomy specimens from patients with prostate cancer. Am J Clin Pathol 2003; 120: 386-91 (Pubitemid 37295109)
55. Presti JC,. Prostate biopsy: current status and limitations. Rev Urol 2007; 9: 93-8
56. Maggi-Galluzzi C, Roma A, Jones S, Klein EA, Zhou M,. The pathologic features of single-nodule prostatic carcinoma. Lab Invest 2006; 86: 148A (Abstract #684)
57. Autorino R, Di Lorenzo G, Damiano R, et al,. Pathology of the prostate in radical cystectomy specimens: a critical review. Surg Oncol 2009; 18: 73-84
58. van Oort IM, Kok DE, Kiemeney LA, Hulsbergen-van de Kaa CA, Witjes JA,. A single institution experience with biochemical recurrence after radical prostatectomy for tumors that on pathology are of small volume or 'insignificant'. Urol Oncol 2009; 27: 509-13
59. Harnden P, Naylor B, Shelley MD, Clements H, Coles B, Mason MD,. The clinical management of patients with a small volume of prostatic cancer on biopsy: what are the risks of progression? A systematic review and meta-analysis. Cancer 2008; 112: 971-81 (Pubitemid 351304580)
60. Epstein JI, Carmichael MJ, Partin AW, Walsh PC,. Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for nonpalpable disease: pathogenetic and clinical implications. J Urol 1994; 151: 1587-92 (Pubitemid 24151309)
61. Sengupta S, Blute ML, Bagniewski SM, et al,. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer. BJU Int 2008; 101: 170-4 (Pubitemid 350294048)
62. Dugan JA, Bostwick DG, Myers RP, Qian J, Bergstralh EJ, Oesterling JE,. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996; 275: 288-94 (Pubitemid 26028587)
63. Jeldres C, Suardi N, Walz J, et al,. Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. Eur Urol 2008; 54: 1306-13
64. Liu W, Laitinen S, Khan S, et al,. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009; 15: 559-65
65. Mehra R, Tomlins SA, Yu J, et al,. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 2008; 68: 3584-90
66. Wolters T, Roobol MJ, van Leeuwen PJ, et al,. Should pathologists routinely report prostate tumour volume? The prognostic value of tumour volume in prostate cancer. Eur Urol 2010; 57: 753-60
67. Guzzo TJ, Vira MA, Neway W, et al,. Minimal tumor volume may provide additional prognostic information in good performance patients after radical prostatectomy. Urology 2007; 69: 1147-51 (Pubitemid 46891574)
68. Rampersaud EN, Sun L, Moul JW, Madden J, Freedland SJ,. Percent tumor involvement and risk of biochemical progression after radical prostatectomy. J Urol 2008; 180: 571-6; discussion 576
69. Chung B, Tarin T, Ferrari M, Brooks J,. Comparison of prostate cancer tumor volume and percent cancer in prediction of biochemical recurrence and cancer specific survival. Urol Oncol 2009; PMED 19837617
70. Hollenbeck BK, Bassily N, Wei JT, et al,. Whole mounted radical prostatectomy specimens do not increase detection of adverse pathological features. J Urol 2000; 164: 1583-6
71. Stephenson AJ, Kattan MW, Eastham JA, et al,. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009; 27: 4300-5
72. de la Rosette J, Mouraviev V, Polascik T,. Focal targeted therapy will be a future treatment modality for early stage prostate cancer. Eur Urol Suppl 2009; 8: 424-32
73. Mazzucchelli R, Scarpelli M, Cheng L, et al,. Pathology of prostate cancer and focal therapy ('male lumpectomy'). Anticancer Res 2009; 29: 5155-61
74. Chan TY, Partin AW, Walsh PC, Epstein JI,. Prognostic significance of Gleason score 3 + 4 versus Gleason score 4 + 3 tumor at radical prostatectomy. Urology 2000; 56: 823-7
75. Guimaraes MS, Quintal MM, Meirelles LR, Magna LA, Ferreira U, Billis A,. Gleason score as predictor of clinicopathologic findings and biochemical (PSA) progression following radical prostatectomy. Int Braz J Urol 2008; 34: 23-9
76. Tollefson MK, Leibovich BC, Slezak JM, Zincke H, Blute ML,. Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival. J Urol 2006; 175: 547-51 (Pubitemid 43067350)
77. Jones JS,. Prostate cancer: are we over-diagnosing-or under-thinking? Eur Urol 2008; 53: 10-2 (Pubitemid 350166731)
78. Burdick MJ, Reddy CA, Ulchaker J, et al,. Comparison of biochemical relapse-free survival between primary Gleason score 3 and primary Gleason score 4 for biopsy Gleason score 7 prostate cancer. Int J Radiat Oncol Biol Phys 2009; 73: 1439-45
79. Stark JR, Perner S, Stampfer MJ, et al,. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 2009; 27: 3459-64
80. Bouye S, Potiron E, Puech P, Leroy X, Lemaitre L, Villers A,. Transition zone and anterior stromal prostate cancers: zone of origin and intraprostatic patterns of spread at histopathology. Prostate 2009; 69: 105-13
81. Lemaitre L, Puech P, Poncelet E, et al,. Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings. Eur Radiol 2009; 19: 470-80